| Literature DB >> 20729996 |
Abstract
DNA-based tests are increasingly being used to predict a blood group phenotype. This is possible because genes encoding 29 of the 30 blood group systems have been cloned and sequenced, and the molecular bases associated with most antigens have been determined. RBCs carrying a particular antigen, if introduced into the circulation of an individual who lacks that antigen, can elicit an immune response. It is the antibody from such an immune response that causes problems in clinical practice and the reason why antigen-negative blood is required for safe transfusion. The classical method of testing for blood group antigens and antibodies is hemagglutination; however, it has certain limitations, some of which can be overcome by testing DNA. Such testing allows conservation of antibodies for confirmation by hemagglutination of predicted antigen-negativity. High-throughput platforms provide a means to test relatively large numbers of donors, thereby opening the door to change the way antigen-negative blood is provided to patients. This chapter discusses how molecular approaches can be applied in transfusion medicine, and summarizes experiences of using laboratory developed tests and DNA arrays at the New York Blood Center.Entities:
Year: 2009 PMID: 20729996 PMCID: PMC2924736 DOI: 10.1159/000212062
Source DB: PubMed Journal: Transfus Med Hemother ISSN: 1660-3796 Impact factor: 3.747